BR112022020438A2 - Composições compreendendo três proteínas de fusão ospa para uso médico - Google Patents
Composições compreendendo três proteínas de fusão ospa para uso médicoInfo
- Publication number
- BR112022020438A2 BR112022020438A2 BR112022020438A BR112022020438A BR112022020438A2 BR 112022020438 A2 BR112022020438 A2 BR 112022020438A2 BR 112022020438 A BR112022020438 A BR 112022020438A BR 112022020438 A BR112022020438 A BR 112022020438A BR 112022020438 A2 BR112022020438 A2 BR 112022020438A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- ospa
- fusion proteins
- medical use
- ospa fusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
COMPOSIÇÕES COMPREENDENDO TRÊS PROTEÍNAS DE FUSÃO OSPA PARA USO MÉDICO. A presente invenção refere-se a uma composição compreendendo a proteína de fusão OspA de SEQ ID NO: 1 (LipS1D1-S2D1), a proteína de fusão OspA de SEQ ID NO: 2 (Lip-S4D1-S3hybD1) e a proteína de fusão OspA de SEQ ID NO : 3 (Lip-S5D1-S6D1) para uso em uma vacina ou para uso em um método para induzir uma resposta imune em um ser humano contra a doença de Lyme.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20169148 | 2020-04-09 | ||
EP20169147 | 2020-04-09 | ||
EP20169642 | 2020-04-15 | ||
EP20187283 | 2020-07-22 | ||
EP20202816 | 2020-10-20 | ||
US202163152582P | 2021-02-23 | 2021-02-23 | |
PCT/US2021/026599 WO2021207615A1 (en) | 2020-04-09 | 2021-04-09 | Compositions comprising three ospa fusion proteins for medical use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022020438A2 true BR112022020438A2 (pt) | 2022-11-29 |
Family
ID=75581705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022020438A BR112022020438A2 (pt) | 2020-04-09 | 2021-04-09 | Composições compreendendo três proteínas de fusão ospa para uso médico |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230173051A1 (pt) |
EP (1) | EP4132950A1 (pt) |
JP (1) | JP2023522170A (pt) |
KR (1) | KR20220167305A (pt) |
CN (1) | CN115698044A (pt) |
AU (1) | AU2021254265A1 (pt) |
BR (1) | BR112022020438A2 (pt) |
CA (1) | CA3174892A1 (pt) |
IL (1) | IL297166A (pt) |
MX (1) | MX2022012647A (pt) |
WO (1) | WO2021207615A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3059817A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
WO2023212520A1 (en) | 2022-04-25 | 2023-11-02 | Pfizer Inc. | Compositions and methods for eliciting an immune response protective against lyme disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
JP6505110B2 (ja) | 2014-01-09 | 2019-04-24 | バルネバ オーストリア ゲーエムベーハ— | OspAの突然変異体断片、並びにそれに関する方法および使用 |
CA3059817A1 (en) * | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
-
2021
- 2021-04-09 AU AU2021254265A patent/AU2021254265A1/en active Pending
- 2021-04-09 KR KR1020227039114A patent/KR20220167305A/ko active Search and Examination
- 2021-04-09 BR BR112022020438A patent/BR112022020438A2/pt unknown
- 2021-04-09 WO PCT/US2021/026599 patent/WO2021207615A1/en active Application Filing
- 2021-04-09 EP EP21720149.0A patent/EP4132950A1/en active Pending
- 2021-04-09 JP JP2022561414A patent/JP2023522170A/ja active Pending
- 2021-04-09 US US17/917,624 patent/US20230173051A1/en active Pending
- 2021-04-09 IL IL297166A patent/IL297166A/en unknown
- 2021-04-09 MX MX2022012647A patent/MX2022012647A/es unknown
- 2021-04-09 CN CN202180039595.XA patent/CN115698044A/zh active Pending
- 2021-04-09 CA CA3174892A patent/CA3174892A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115698044A (zh) | 2023-02-03 |
CA3174892A1 (en) | 2021-10-14 |
EP4132950A1 (en) | 2023-02-15 |
KR20220167305A (ko) | 2022-12-20 |
WO2021207615A1 (en) | 2021-10-14 |
US20230173051A1 (en) | 2023-06-08 |
MX2022012647A (es) | 2023-01-16 |
IL297166A (en) | 2022-12-01 |
JP2023522170A (ja) | 2023-05-29 |
AU2021254265A1 (en) | 2022-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kaba et al. | Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine | |
UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
BRPI0407877A (pt) | conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente | |
BR112022020438A2 (pt) | Composições compreendendo três proteínas de fusão ospa para uso médico | |
JP6874031B2 (ja) | アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法 | |
Singh et al. | A Plasmodium falciparum 48/45 single epitope R0. 6C subunit protein elicits high levels of transmission blocking antibodies | |
Martinez-Campos et al. | Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice | |
Earnhart et al. | An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences | |
ES2581981T3 (es) | Polipéptidos de Streptococcus suis y polinucleótidos codificantes de los mismos y su utilización en aplicaciones vacunales y diagnósticas | |
BR0312537A (pt) | Usos de hidrolisato de proteìna de soro em composição comestìvel, método de indução da saciedade em seres humanos ou animais e método de melhoria ou controle da percepção da imagem do corpo e/ou controle do peso do corpo e/ou controle da ingestão de calorias e/ou auxìlio na adesão a um plano de dieta | |
NO20111324A1 (no) | Rekombinant MVA-virus | |
BRPI0905725B1 (pt) | vacina e embalagem farmacêutica | |
Rafati et al. | Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients | |
Solioz et al. | The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis | |
Pacífico et al. | Immunization with Schistosoma mansoni 22.6 kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine | |
Hassan et al. | Immunoglobulin and cytokine changes induced following immunization with a DNA vaccine encoding Toxoplasma gondii selenium-dependent glutathione reductase protein | |
CN108578679A (zh) | 嵌合ksac蛋白的表达和由高压产生可溶性蛋白的方法 | |
CN101451145B (zh) | 基于t细胞表位的结核基因疫苗及其制备方法和应用 | |
Sen et al. | Hookworm burden reductions in BALB/c mice vaccinated with recombinant Ancylostoma secreted proteins (ASPs) from Ancylostoma duodenale, Ancylostoma caninum and Necator americanus | |
BR112022026580A2 (pt) | Composições e métodos para induzir uma resposta imune contra coronavírus | |
BR112021020777A2 (pt) | Vacina de subunidade do csfv | |
Horká et al. | Tick saliva affects both proliferation and distribution of Borrelia burgdorferi spirochetes in mouse organs and increases transmission of spirochetes to ticks | |
EP1556513A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS | |
RU2020106669A (ru) | Синтетические белки и пути их терапевтического применения | |
WO2006072946A3 (en) | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation |